UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053231
Receipt number R000060745
Scientific Title An examination study of the anti-stress effect by the test food consumption: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2023/12/26
Last modified on 2024/03/15 10:10:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

An examination study of the anti-stress effect by the test food consumption

Acronym

An examination study of the anti-stress effect by the test food consumption

Scientific Title

An examination study of the anti-stress effect by the test food consumption: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

An examination study of the anti-stress effect by the test food consumption

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the anti-stress effect of consumption of the test food

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The measured value of Total Mood Disturbance (TMD), Tension-Anxiety (TA), Depression-Dejection (DD), Anger-Hostility (AH), Vigor-Activity (VA), Fatigue-Inertia (FI), Confusion-Bewilderment (CB), and Friendliness (F) in the Profile of Mood States 2nd Edition (POMS2) at four weeks after consumption (4w)

Key secondary outcomes

1. Each item in the POMS2 at 4w

2. "Sleepiness on rising", "Initiation and maintenance of sleep", "frequent dreaming", "refreshing", "sleep length", and each item in the OSA sleep inventory MA version (OSA-MA) at 4w

3. Total score in the Athens Insomnia Scale (AIS) at 4w

4. Each item in the AIS at 4w

5. The measured values of salivary cortisol at 4w

6. The gut microbiota, intestinal metabolites, blood metabolites, and blood hormone at 4w


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Duration: Four weeks
Test food: Powdered food 1

Interventions/Control_2

Duration: Four weeks
Test food: Powdered food 2

Interventions/Control_3

Duration: Four weeks
Test food: Placebo food

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Individuals aged 30 or more and less than 60

4. Healthy individuals

5. Individuals who are judged as eligible to participate in the study by the physician according to the results of the Beck depression inventory (BDI-II) at screening

6. Individuals whose Total Mood Disturbance (TMD) score in the Profile of Mood States 2nd Edition (POMS2) is high among those who meet inclusion criteria No.1~5 without meeting any of exclusion criteria

Key exclusion criteria

Individuals who
1. are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. are currently undergoing medical treatment or have a medical history of insomnia or sleep disorder
5. are currently undergoing medical treatment or have a medical history of psychiatric disorder such as depression disorder
6. are currently undergoing medical treatment or have a medical history of chronic fatigue syndrome
7. are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
8. are taking medications, "Foods for Specified Health Uses," "Foods with Functional Claims," or supplements which may affect fatigue or sleep
9. are taking medications (including herbal medicines) and supplements
10. are allergic to medicines and/or the test food related products
11. are pregnant, lactating, or planning to become pregnant during this study
12. sleep with more than one person
13. have irregular sleeping time or habit due to work such as a late-night shift
14. need to get up in the middle of the night for childcare or nursing care
15. have irregular lifestyles (such as not working full-time, not eating meals at regular intervals, or not sleeping enough)
16. usually drink to excess (average of more than about 20 g/day as absolute alcohol intake)
17. have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate another study during this study
18. are judged as ineligible to participate in this study by the physician

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

Combi Corporation.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

36

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 12 Month 13 Day

Date of IRB

2023 Year 12 Month 13 Day

Anticipated trial start date

2023 Year 12 Month 26 Day

Last follow-up date

2024 Year 04 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 26 Day

Last modified on

2024 Year 03 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060745


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name